Max Levin
Impact in
- Oncology top 5%
- Cancer Immunotherapy and Biomarkers
- Cutaneous Melanoma Detection and Management
- Biochemistry top 5%
- Lipid metabolism and biosynthesis
Papers in
- Immunology 12
- Atherosclerosis and Cardiovascular Diseases 12
- Oncology 13
- Cancer Immunotherapy and Biomarkers 8
- Cutaneous Melanoma Detection and Management 3
- Co-authors
- Tom Björnheden (4 shared papers)Olov Wiklund (5 shared papers)Lillemor Mattsson Hultén (5 shared papers)Jan Borén (15 shared papers)Marcus Ståhlman (4 shared papers)Lars Ny (12 shared papers)Angelo Limeta (2 shared papers)Jens Nielsen (2 shared papers)
- Journals
- PLoS ONE (4 papers)Arteriosclerosis Thrombosis and Vascular Biology (4 papers)The Lancet Oncology (3 papers)Atherosclerosis (2 papers)Acta Oncologica (2 papers)
- Partner nations
- SwedenUnited StatesNorway
In The Last Decade
Max Levin
55 papers receiving 2.4k citations
Max Levin's Hit Papers
Peers
Comparison fields: 5 of 94
- Oncology 582
- Biochemistry 111
- Immunology 319
- Cancer Research 156
- Nephrology 107
Countries citing papers authored by Max Levin
This map shows the geographic impact of Max Levin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Max Levin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Max Levin more than expected).
Fields of papers citing papers by Max Levin
This network shows the impact of papers produced by Max Levin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Max Levin. The network helps show where Max Levin may publish in the future.
Co-authors
The 25 scholars most cited alongside Max Levin, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 55 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial Hit paper breakdown → | 2021 | 300 |
| 2 | 1999 | 250 | |
| 3 | 2016 | 233 | |
| 4 | 2013 | 152 | |
| 5 | The PEMDAC phase 2 study of pembrolizumab and entinostat in patients with metastatic uveal melanoma Hit paper breakdown → | 2021 | 137 |
| 6 | 2020 | 129 | |
| 7 | 2009 | 89 | |
| 8 | 2006 | 83 | |
| 9 | 2000 | 65 | |
| 10 | 2004 | 59 | |
| 11 | 2021 | 59 | |
| 12 | 2019 | 55 | |
| 13 | 2022 | 55 | |
| 14 | 2016 | 54 | |
| 15 | 2012 | 51 | |
| 16 | 2019 | 50 | |
| 17 | 2012 | 42 | |
| 18 | 2007 | 41 | |
| 19 | 2019 | 41 | |
| 20 | 2018 | 39 |
About Max Levin
Max Levin is a scholar working on Immunology, Oncology, Ophthalmology, Biochemistry and Molecular Biology, having authored 55 papers that have together received 2.5k indexed citations. Recurring topics across this work include Atherosclerosis and Cardiovascular Diseases (12 papers), Cancer Immunotherapy and Biomarkers (8 papers), Ocular Oncology and Treatments (5 papers), Cardiovascular Conditions and Treatments (3 papers), Lipid metabolism and biosynthesis (3 papers), Cutaneous Melanoma Detection and Management (3 papers), Cardiovascular Function and Risk Factors (3 papers) and Angiogenesis and VEGF in Cancer (3 papers). The work is most often cited by research in Oncology (582 citations), Biochemistry (111 citations), Immunology (319 citations), Cancer Research (156 citations) and Nephrology (107 citations). Max Levin has collaborated with scholars based in Sweden, United States and Norway. Frequent co-authors include Tom Björnheden, Olov Wiklund, Lillemor Mattsson Hultén, Jan Borén, Marcus Ståhlman, Lars Ny, Angelo Limeta, Jens Nielsen, Francesco Gatto and Boyang Ji. Their work appears in journals such as PLoS ONE, Arteriosclerosis Thrombosis and Vascular Biology, The Lancet Oncology, Atherosclerosis and Acta Oncologica.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.